Tumor specific delivery and therapy by double-targeted nanostructured lipid carriers with anti-VEGFR-2 antibody.
Donghua Liu,Fengxi Liu,2 Authors,N. Zhang
2011 · DOI: 10.1021/mp200402e
Molecular Pharmaceutics · 98 Citations
TLDR
It is suggested that tNLC designed to bind specifically to VEGFR-2 can be used to deliver DTX to the tumor vasculature and tumor and may inhibit tumor growth.
Cited Papers
Citing Papers